Multicenter, open, randomized study with active control (isoniazid) to evaluate the early
antibacterial activity, safety and pharmacokinetics of the drug PBTZ169 (capsules 80 mg) when
used in patients with first-diagnosed tuberculosis of the respiratory system with bacterial
excretion and saved bacterial susceptibility to isoniazid and rifampicin